Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 49
Filter
Add more filters










Publication year range
1.
Kokubyo Gakkai Zasshi ; 81(3)-82(1): 8-14, 2015 Mar.
Article in Japanese | MEDLINE | ID: mdl-26043556

ABSTRACT

Glucagon-like peptide 1 (GLP-1) is the gastrointestinal hormone released from L-cells of the small intestine and promotes insulin secretion by acting on the pancreas islet. GLP-1 receptor (GLP-1R) expression has been detected in many organs that are involved in carbohydrate metabolism, however its expression in the salivary glands, which participate in the first carbohydrate metabolism, has not been clarified yet. Furthermore, it is known that occlusion affects both the morphology and function of the salivary glands. Thus in this study, we focused on the expression of GLP-1R in the major salivary glands, and analyzed the changes of GLP-1R expression under the occlusal changes. Twenty-four male Wistar rats were used in this study. In the experimental group, all maxillary molars were extracted at 7 weeks old. The rats without molar extraction were used as the control group. The rats were sacrificed at 8 and 11 weeks old, then the parotid gland (PG), submandibular gland (SMG), and sublingual gland (SLG) were analyzed immunohistochemically for the presence of GLP-1R. Immunohistochemical staining showed GLP-1R to be localized in the ductal cells of PG, SMG, and SLG. In SLG, there were no differences in the intensity of GLP-1R staining in both the control and experimental groups at 8 and 11 weeks old. In PG and SMG, the intensity of GLP-1R staining in the experimental group was significantly weaker than in the control group at 11 weeks old, otherwise there were no differences at 8 weeks old. In conclusion, GLP-1R is expressed in rat PG, SMG, and SLG, and its expression can be influenced by molar extraction.


Subject(s)
Molar/surgery , Receptors, Glucagon/analysis , Salivary Glands/chemistry , Tooth Extraction , Animals , Glucagon-Like Peptide-1 Receptor , Immunohistochemistry , Male , Rats , Rats, Wistar , Receptors, Glucagon/metabolism
2.
Bioconjug Chem ; 26(2): 329-37, 2015 Feb 18.
Article in English | MEDLINE | ID: mdl-25594741

ABSTRACT

Peptides display many characteristics of efficient imaging agents such as rapid targeting, fast background clearance, and low non-specific cellular uptake. However, poor stability, low affinity, and loss of binding after labeling often preclude their use in vivo. Using glucagon-like peptide-1 receptor (GLP-1R) ligands exendin and GLP-1 as a model system, we designed a novel α-helix-stabilizing linker to simultaneously address these limitations. The stabilized and labeled peptides showed an increase in helicity, improved protease resistance, negligible loss or an improvement in binding affinity, and excellent in vivo targeting. The ease of incorporating azidohomoalanine in peptides and efficient reaction with the dialkyne linker enable this technique to potentially be used as a general method for labeling α helices. This strategy should be useful for imaging beta cells in diabetes research and in developing and testing other peptide targeting agents.


Subject(s)
Glucagon-Like Peptide 1/chemistry , Insulin-Secreting Cells/metabolism , Peptides/chemistry , Receptors, Glucagon/analysis , Receptors, Glucagon/metabolism , Venoms/chemistry , Amino Acid Sequence , Animals , Exenatide , Glucagon-Like Peptide 1/metabolism , Glucagon-Like Peptide-1 Receptor , Histological Techniques , Insulin-Secreting Cells/cytology , Ligands , Mice , Mice, Inbred C57BL , Microscopy , Models, Molecular , Molecular Sequence Data , Optical Imaging , Pancreatic Neoplasms/metabolism , Peptides/metabolism , Protein Stability , Protein Structure, Secondary , Venoms/metabolism
4.
Theranostics ; 4(8): 770-7, 2014.
Article in English | MEDLINE | ID: mdl-24955138

ABSTRACT

The Glucagon-like peptide 1 receptor (GLP-1R) has become an important target for imaging due to its elevated expression profile in pancreatic islets, insulinoma, and the cardiovascular system. Because native GLP-1 is degraded rapidly by dipeptidyl peptidase-IV (DPP-IV), several studies have conjugated different chelators to a more stable analog of GLP-1 (such as exendin-4) as PET or SPECT imaging agents with various advantages and disadvantages. Based on the recently developed Sarcophagin chelator, here, we describe the construction of GLP-1R targeted PET probes containing monomeric and dimeric exendin-4 subunit. The in vitro binding affinity of BarMalSar-exendin-4 and Mal2Sar-(exendin-4)2 was evaluated in INS-1 cells, which over-express GLP-1R. Mal2Sar-(exendin-4)2 demonstrated around 3 times higher binding affinity compared with BaMalSar-exendin-4. After (64)Cu labeling, microPET imaging of (64)Cu-BaMalSar-exendin-4 and (64)Cu-Mal2Sar-(exendin-4)2 were performed on subcutaneous INS-1 tumors, which were clearly visualized with both probes. The tumor uptake of (64)Cu-Mal2Sar-(exendin-4)2 was significantly higher than that of (64)Cu-BaMaSarl-exendin-4, which could be caused by polyvalency effect. The receptor specificity of these probes was confirmed by effective blocking of the uptake in both tumor and normal positive organs with 20-fold excess of unlabeled exendin-4. In conclusion, sarcophagine cage conjugated exendin-4 demonstrated persistent and specific uptake in INS-1 insulinoma model. Dimerization of exendin-4 could successfully lead to increased tumor uptake in vivo. Both (64)Cu-BaMalSar-exendin-4 and (64)Cu-Mal2Sar-(exendin-4)2 hold a great potential for GLP-1R targeted imaging.


Subject(s)
Copper Radioisotopes , Dipeptides , Peptides , Positron-Emission Tomography , Receptors, Glucagon/metabolism , Venoms , Animals , Blotting, Western , Cell Line, Tumor , Dipeptides/chemistry , Exenatide , Fluorescent Antibody Technique , Glucagon-Like Peptide-1 Receptor , Humans , Male , Mice, Inbred NOD , Mice, SCID , Peptides/chemical synthesis , Peptides/chemistry , Rats , Receptors, Glucagon/analysis , Venoms/chemical synthesis , Venoms/chemistry
5.
Bioconjug Chem ; 25(7): 1323-30, 2014 Jul 16.
Article in English | MEDLINE | ID: mdl-24856928

ABSTRACT

Accurate visualization and quantification of ß-cell mass is critical for the improved understanding, diagnosis, and treatment of both type 1 diabetes (T1D) and insulinoma. Here, we describe the synthesis of a bimodal imaging probe (PET/fluorescence) for imaging GLP-1R expression in the pancreas and in pancreatic islet cell tumors. The conjugation of a bimodal imaging tag containing a near-infrared fluorescent dye, and the copper chelator sarcophagine to the GLP-1R targeting peptide exendin-4 provided the basis for the bimodal imaging probe. Conjugation was performed via a novel sequential one-pot synthetic procedure including (64)Cu radiolabeling and copper-catalyzed click-conjugation. The bimodal imaging agent (64)Cu-E4-Fl was synthesized in good radiochemical yield and specific activity (RCY = 36%, specific activity: 141 µCi/µg, >98% radiochemical purity). The agent showed good performance in vivo and ex vivo, visualizing small xenografts (<2 mm) with PET and pancreatic ß-cell mass by phosphor autoradiography. Using the fluorescent properties of the probe, we were able to detect individual pancreatic islets, confirming specific binding to GLP-1R and surpassing the sensitivity of the radioactive label. The use of bimodal PET/fluorescent imaging probes is promising for preoperative imaging and fluorescence-assisted analysis of patient tissues. We believe that our procedure could become relevant as a protocol for the development of bimodal imaging agents.


Subject(s)
Adenoma, Islet Cell/metabolism , Copper Radioisotopes , Multimodal Imaging/methods , Optical Imaging/methods , Pancreas/metabolism , Positron-Emission Tomography/methods , Radiopharmaceuticals , Receptors, Glucagon/metabolism , Adenoma, Islet Cell/diagnostic imaging , Adenoma, Islet Cell/drug therapy , Amino Acid Sequence , Animals , Cell Tracking/methods , Cells, Cultured , Exenatide , Female , Fluorescent Antibody Technique , Glucagon-Like Peptide-1 Receptor , Humans , Hypoglycemic Agents/administration & dosage , Mice , Mice, Nude , Molecular Sequence Data , Pancreas/diagnostic imaging , Pancreas/drug effects , Peptides/administration & dosage , Receptors, Glucagon/analysis , Venoms/administration & dosage , Xenograft Model Antitumor Assays
6.
J Histochem Cytochem ; 61(9): 649-58, 2013 Sep.
Article in English | MEDLINE | ID: mdl-23803499

ABSTRACT

The stomach is a target organ of the incretin hormone glucagon-like peptide-1 (GLP-1). However, the cellular expression and glandular distribution of its receptor (GLP-1R) in human gastric mucosa are not known. We determined the expression of GLP-1R in different regions of human stomach mucosa and its specific cellular association and distribution within gastric glands. Tissue samples from stomach body and antrum were obtained from 20 patients during routine esophagogastroduodenoscopy. mRNA encoding GLP-1R protein expression was evaluated by RT-PCR. Determination of cell types bearing GLP-1R, their localization, and their frequency in gastric glands in different gastric regions were estimated by immunohistochemical morphological analysis. Levels of GLP-1R mRNA were similar in body and antrum. GLP-1R immunoreactivity was found throughout the gastric mucosa in various types of glandular cells. The highest frequency of GLP-1R immunoreactive cells was found in the neck area of the principal glands in cells morphologically identified as parietal cells. GLP-1R immunostaining was also found on enteroendocrine-like cells in the pyloric glands. This study provides the first description of GLP-1R expression in human gastric glands and its specific cellular association. Our data suggest that GLP-1 may act directly on the gastric mucosa to modulate its complex functions.


Subject(s)
Gastric Mucosa/metabolism , Receptors, Glucagon/analysis , Receptors, Glucagon/genetics , Adult , Aged , Female , Gastric Mucosa/ultrastructure , Gene Expression , Glucagon-Like Peptide-1 Receptor , Humans , Immunohistochemistry , Male , Middle Aged , RNA, Messenger/analysis , RNA, Messenger/genetics , Real-Time Polymerase Chain Reaction , Young Adult
7.
Recent Results Cancer Res ; 194: 567-76, 2013.
Article in English | MEDLINE | ID: mdl-22918784

ABSTRACT

A precise definition of the tumor tissue targets to be selected for in vivo peptide receptor targeting, namely to know which peptide receptor is expressed in which type of cancer, is an important prerequisite for successful clinical application of this technology. In this short review, I give three selected examples of new and promising peptide receptor targets. In the somatostatin receptor field, based on in vitro receptor autoradiography experiments showing that much more sst(2) binding sites are detected in tumors using a (177)Lu-labeled sst(2) antagonist than a (177)Lu-labeled agonist, it can be proposed that, in addition to neuroendocrine tumors, nonneuroendocrine tumors with lower sst(2) levels such as breast carcinomas, renal cell carcinomas, and non-Hodgkin lymphomas may become potential candidates for sst(2) antagonist targeting. In the gastrin-releasing peptide receptor field, recent in vitro data show that not only tumor cells may overexpress gastrin-releasing peptide receptors but also neoangiogenic tumoral vessels, making tumors expressing high levels of gastrin-releasing peptide receptors in tumor vessels, such as ovarian or urinary tract cancers, attractive new candidates for gastrin-releasing peptide receptor targeting. In the incretin receptor field, it was found in vitro that, apart from glucagon-like peptide 1 receptors overexpressed in benign insulinomas, incretin receptors, especially the glucose-dependent insulinotropic polypeptide receptors, can be overexpressed in medullary thyroid cancers, an unexpected finding making also these tumors potential novel candidates for incretin receptor targeting. Due to the abundance of peptide receptors in various cancers, it may be possible in the future to define for each tumor type a corresponding overexpressed peptide receptor suitable for targeting.


Subject(s)
Neoplasms/radiotherapy , Neuroendocrine Tumors/radiotherapy , Radiopharmaceuticals/therapeutic use , Receptors, Bombesin/analysis , Receptors, Glucagon/analysis , Receptors, Somatostatin/analysis , Glucagon-Like Peptide-1 Receptor , Humans , Neoplasms/chemistry , Neuroendocrine Tumors/chemistry
8.
Eur J Nucl Med Mol Imaging ; 40(4): 524-31, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23224740

ABSTRACT

PURPOSE: The objective of this article is to present a new method for the diagnosis of insulinoma with the use of [Lys(40)(Ahx-HYNIC-(99m)Tc/EDDA)NH2]-exendin-4. METHODS: Studies were performed in 11 patients with negative results of all available non-isotopic diagnostic methods (8 with symptoms of insulinoma, 2 with malignant insulinoma and 1 with nesidioblastosis). In all patients glucagon-like peptide-1 (GLP-1) receptor imaging (whole-body and single photon emission computed tomography/CT examinations) after the injection of 740 MBq of the tracer was performed. RESULTS: Both sensitivity and specificity of GLP-1 receptor imaging were assessed to be 100 % in patients with benign insulinoma. In all eight cases with suspicion of insulinoma a focal uptake in the pancreas was found. In six patients surgical excision of the tumour was performed (type G1 tumours were confirmed histopathologically). In one patient surgical treatment is planned. One patient was disqualified from surgery. In one case with malignant insulinoma pathological accumulation of the tracer was found only in the region of local recurrence. The GLP-1 study was negative in the other malignant insulinoma patient. In one case with suspicion of nesidioblastosis, a focal accumulation of the tracer was observed and histopathology revealed coexistence of insulinoma and nesidioblastosis. CONCLUSION: [Lys(40)(Ahx-HYNIC-(99m)Tc/EDDA)NH2]-exendin-4 seems to be a promising diagnostic tool in the localization of small insulinoma tumours, but requires verification in a larger series of patients.


Subject(s)
Insulinoma/diagnostic imaging , Organotechnetium Compounds , Pancreatic Neoplasms/diagnostic imaging , Peptides , Radiopharmaceuticals , Receptors, Glucagon/analysis , Adolescent , Adult , Aged , Exenatide , Female , Glucagon-Like Peptide-1 Receptor , Humans , Hydrazines/chemistry , Hypoglycemic Agents/chemistry , Hypoglycemic Agents/metabolism , Male , Middle Aged , Nicotinic Acids/chemistry , Organotechnetium Compounds/chemistry , Peptides/chemistry , Peptides/metabolism , Radionuclide Imaging , Radiopharmaceuticals/chemistry , Receptors, Glucagon/metabolism , Venoms/chemistry , Venoms/metabolism , Young Adult
9.
Endocrinol. nutr. (Ed. impr.) ; 59(9): 523-530, nov. 2012. ilus, tab
Article in English | IBECS | ID: ibc-106364

ABSTRACT

Background and aim We have described a novel Mahvash disease of hyperglucagonemia and pancreatic neuroendocrine tumors (PNETs) associated with an inactivating glucagon receptor mutation, and identified the glucagon receptor-deficient (..) (AU)


Antecedentes y objetivo: Hemos descrito la nueva enfermedad de Mahvash en la que existen hiperglucagonemia y tumores neuroendocrinos pancreáticos (TNEP) asociados con una mutación inactivante del receptor de glucagón, e (..) (AU)


Subject(s)
Animals , Mice , Receptors, Glucagon/analysis , Glucagon/metabolism , Neuroendocrine Tumors/physiopathology , Pancreatic Neoplasms/physiopathology , Disease Models, Animal , Mice
10.
J Dairy Sci ; 95(9): 5089-5094, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22916913

ABSTRACT

The role of distal gut signals in control of feed intake and metabolism in cattle has received scant attention. Peptide YY (PYY) and glucagon-like peptide-1, which are secreted from enteroendocrine cells of the distal gut in monogastrics have several functions, including regulation of energy balance. However, little is known of the tissue expression of these peptides and their receptors in cattle. The aim of the current study was to characterize the tissue distribution of PYY, neuropeptide Y receptor Y2 (Y2), proglucagon (GCG), and glucagon-like peptide-1 receptor (GLP1R) in various peripheral tissues of cattle. Four male 7-wk-old dairy calves were euthanized and 16 peripheral tissues were collected. Conventional PCR and quantitative real-time PCR were performed to confirm tissue expression and quantify the transcript abundance in various tissues. The results of conventional PCR revealed that mRNA for both PYY and Y2 was detectable in the rumen, abomasum, duodenum, jejunum, ileum, and colon but not in other tissues. Quantitative real-time PCR data demonstrated that PYY mRNA was 2- to 3-fold greater in the pancreas, kidney, and heart relative to the liver. By conventional PCR, GCG mRNA was detected in the abomasum, duodenum, jejunum, ileum, and colon and GLP1R mRNA was expressed in all gut segments, pancreas, spleen, and kidney. Quantitative real-time PCR data demonstrated that, relative to transcript abundance in the liver, GCG mRNA was 4- to 40-fold higher from abomasum to colon, and GLP1R mRNA was 50- to 300-fold higher from the rumen to colon, 14-fold greater in the pancreas, 18-fold higher in the spleen, and 166-fold greater in the kidney. The tissue distribution of PYY, GCG, and their receptors observed in the current study is, in general, consistent with expression patterns in monogastrics. The predominant expression of PYY, Y2, and GCG in the gut, and the presence of GLP1R in multiple peripheral tissues suggest a role for PYY in controlling gut functions and for GLP-1 in regulating multiple physiological functions in cattle.


Subject(s)
Cattle/physiology , Neuropeptide Y/physiology , Peptide YY/physiology , Proglucagon/physiology , Receptors, Glucagon/physiology , Receptors, Neuropeptide Y/physiology , Animals , Cattle/metabolism , Digestive System/chemistry , Digestive System/metabolism , Glucagon-Like Peptide-1 Receptor , Male , Neuropeptide Y/analysis , Peptide YY/analysis , Proglucagon/analysis , Real-Time Polymerase Chain Reaction/veterinary , Receptors, Glucagon/analysis , Receptors, Neuropeptide Y/analysis
11.
Biochem Biophys Res Commun ; 412(3): 413-8, 2011 Sep 02.
Article in English | MEDLINE | ID: mdl-21820405

ABSTRACT

A critical unmet need exists for methods to quantitatively measure endogenous pancreatic ß-cell mass (BCM) for the clinical evaluation of therapies to prevent or reverse loss of BCM and diabetes progression. Our objective was to identify G-protein coupled receptors (GPCRs) that are expressed with a high degree of specificity to islet ß-cells for receptor-targeted imaging of BCM. GPCRs enriched in pancreatic islets relative to pancreas acinar and hepatic tissue were identified using a database screen. Islet-specific expression was confirmed by human pancreas immunohistochemistry (IHC). In vitro selectivity assessment was determined from the binding and uptake of radiolabeled ligands to the rat insulinoma INS-1 832/13 cell line and isolated rat islets relative to the exocrine pancreas cell-type, PANC-1. Tail-vein injections of radioligands into rats were used to determine favorable image criteria of in vivo biodistribution to the pancreas relative to other internal organs (i.e., liver, spleen, stomach, and lungs). Database and IHC screening identified four candidate receptors for further in vitro and in vivo evaluation for PET imaging of BCM: prokineticin-1 receptor (PK-1R), metabotropic glutamate receptor type-5 (mGluR5), neuropeptide Y-2 receptor (NPY-2R), and glucagon-like peptide 1 receptor (GLP-1R). In vitro specificity ratios gave the following receptor rank order: PK-1R>GLP-1R>NPY-2R>mGluR5. The biodistribution rank order of selectivity to the pancreas was found to be PK-1R>VMAT2∼GLP-1R>mGluR5. Favorable islet selectivity and biodistribution characteristics suggest several GPCRs as potential targets for PET imaging of pancreatic BCM.


Subject(s)
Insulin-Secreting Cells/metabolism , Positron-Emission Tomography/methods , Receptors, G-Protein-Coupled/metabolism , Animals , Cell Line , Glucagon-Like Peptide-1 Receptor , Humans , Insulin-Secreting Cells/chemistry , Insulin-Secreting Cells/cytology , Ligands , Male , Rats , Rats, Sprague-Dawley , Receptor, Metabotropic Glutamate 5 , Receptors, G-Protein-Coupled/analysis , Receptors, Glucagon/analysis , Receptors, Glucagon/metabolism , Receptors, Metabotropic Glutamate/analysis , Receptors, Metabotropic Glutamate/metabolism , Receptors, Neuropeptide Y/analysis , Receptors, Neuropeptide Y/metabolism , Tissue Distribution
12.
Bioconjug Chem ; 22(8): 1587-94, 2011 Aug 17.
Article in English | MEDLINE | ID: mdl-21692471

ABSTRACT

Glucagon-like peptide 1 receptor (GLP-1R) is highly expressed in pancreatic islets, especially on ß-cells. Therefore, a properly labeled ligand that binds to GLP-1R could be used for in vivo pancreatic islet imaging. Because native GLP-1 is degraded rapidly by dipeptidyl peptidase-IV (DPP-IV), a more stable agonist of GLP-1 such as Exendin-4 is a preferred imaging agent. In this study, DO3A-VS-Cys(40)-Exendin-4 was prepared through the conjugation of DO3A-VS with Cys(40)-Exendin-4. The in vitro binding affinity of DO3A-VS-Cys(40)-Exendin-4 was evaluated in INS-1 cells, which overexpress GLP-1R. After (64)Cu labeling, biodistribution studies and microPET imaging of (64)Cu-DO3A-VS-Cys(40)-Exendin-4 were performed on both subcutaneous INS-1 tumors and islet transplantation models. The subcutaneous INS-1 tumor was clearly visualized with microPET imaging after the injection of (64)Cu-DO3A-VS-Cys(40)-Exendin-4. GLP-1R positive organs, such as pancreas and lung, showed high uptake. Tumor uptake was saturable, reduced dramatically by a 20-fold excess of unlabeled Exendin-4. In the intraportal islet transplantation models, (64)Cu-DO3A-VS-Cys(40)-Exendin-4 demonstrated almost two times higher uptake compared with normal mice. (64)Cu-DO3A-VS-Cys(40)-Exendin-4 demonstrated persistent and specific uptake in the mouse pancreas, the subcutaneous insulinoma mouse model, and the intraportal human islet transplantation mouse model. This novel PET probe may be suitable for in vivo pancreatic islets imaging in the human.


Subject(s)
Cell Tracking/methods , Copper Radioisotopes , Diagnostic Imaging/methods , Islets of Langerhans Transplantation , Islets of Langerhans/cytology , Receptors, Glucagon/analysis , Animals , Exenatide , Glucagon-Like Peptide-1 Receptor , Heterocyclic Compounds, 1-Ring , Humans , Hypoglycemic Agents , Insulinoma/pathology , Mice , Peptides , Radiopharmaceuticals , Tissue Distribution , Venoms , Vinyl Compounds
13.
Nihon Rinsho ; 69(5): 813-20, 2011 May.
Article in Japanese | MEDLINE | ID: mdl-21595264

ABSTRACT

G protein-coupled receptor (GPCR) is integral membrane protein with seven alfa-helices and most diverse families of protein in mammals. It is located on cell membrane and activated by binding neurotransmit proteins and hormones. It has critical role of functional regulation in central nerve system and peripheral organs. Recently, many orphan GPCRs have been identified from the data of genomic sequence in human genomic project. GIP receptor and GLP-1 receptor belong to glucagon receptor subfamily of class B and are widely expressed in many organs. GIP receptor is expressed in intestine, adipose tissue, brain, adrenal gland, and bone, while GLP-1 receptor is expressed in intestine, CNS, lung, kidney and heart. GIP and GLP-1 have not only pancreatic effect, such as potentiation of insulin secretion but also many extrapancreatic effects.


Subject(s)
Receptors, G-Protein-Coupled/physiology , Receptors, Gastrointestinal Hormone/physiology , Receptors, Glucagon/physiology , Glucagon-Like Peptide-1 Receptor , Humans , Receptors, Gastrointestinal Hormone/analysis , Receptors, Glucagon/analysis
14.
Metabolism ; 60(9): 1271-7, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21388644

ABSTRACT

Advanced glycation end products (AGE) and receptor for AGE (RAGE) interaction elicits reactive oxygen species (ROS) generation and inflammatory reactions, thereby being involved in the development and progression of diabetic nephropathy. Recently, we, along with others, found that glucagon-like peptide-1 (GLP-1), one of the incretins and a gut hormone secreted from L cells in the intestine in response to food intake, could have anti-inflammatory and antithrombogenic properties in cultured endothelial cells. However, the effects of GLP-1 on renal mesangial cells are largely unknown. Therefore, to elucidate the role of GLP-1 in diabetic nephropathy, this study investigated whether and how GLP-1 blocked AGE-induced monocyte chemoattractant protein-1 expression in human cultured mesangial cells. Gene and protein expression was analyzed by quantitative real-time reverse transcription polymerase chain reactions, Western blots, and enzyme-linked immunosorbent assay. The ROS generation was measured with dihydroethidium staining. Glucagon-like peptide-1 receptor (GLP-1R) was expressed in mesangial cells. Glucagon-like peptide-1 inhibited RAGE gene expression in mesangial cells, which was blocked by small interfering RNAs raised against GLP-1R. Furthermore, GLP-1 decreased ROS generation and subsequently reduced monocyte chemoattractant protein-1 gene and protein expression in AGE-exposed mesangial cells. An analogue of cyclic adenosine monophosphate mimicked the effects of GLP-1 on mesangial cells. Our present study suggests that GLP-1 may directly act on mesangial cells via GLP-1R and that it could work as an anti-inflammatory agent against AGE by reducing RAGE expression via activation of cyclic adenosine monophosphate pathway.


Subject(s)
Chemokine CCL2/genetics , Glucagon-Like Peptide 1/pharmacology , Glycation End Products, Advanced/antagonists & inhibitors , Mesangial Cells/drug effects , Receptors, Immunologic/analysis , Cells, Cultured , Chemokine CCL2/analysis , Glucagon-Like Peptide-1 Receptor , Glycation End Products, Advanced/physiology , Humans , Mesangial Cells/metabolism , RNA, Messenger/analysis , Reactive Oxygen Species/metabolism , Receptor for Advanced Glycation End Products , Receptors, Glucagon/analysis , Receptors, Glucagon/physiology , Receptors, Immunologic/genetics
17.
J Clin Endocrinol Metab ; 94(11): 4398-405, 2009 Nov.
Article in English | MEDLINE | ID: mdl-19820010

ABSTRACT

CONTEXT: The surgical removal of insulinomas is hampered by difficulties to localize it using conventional radiological procedures. Recently these tumors were shown to exhibit a very high density of glucagon-like peptide-1 receptors (GLP-1R) in vitro that may be used as specific targets for in vivo receptor radiolabeling. OBJECTIVE: The objective of the study was to test the 111In-labeled GLP-1R agonist 111In-DOTA-exendin-4 in localizing insulinomas using single photon emission computed tomography in combination with computed tomography images. DESIGN: This was a prospective open-label investigation. SETTING: The study was conducted at three tertiary referral centers in Switzerland. PATIENTS: Patients included six consecutive patients with proven clinical and biochemical endogenous hyperinsulinemic hypoglycemia. INTERVENTION: (111)In-DOTA-exendin-4 was administered iv at a dose of about 90 MBq (30 microg peptide) over 5 min. Whole-body planar images of the abdomen were performed at 20 min, 4 h, 23 h, 96 h, and up to 168 h after injection. After surgical removal of the insulinomas, GLP-1R expression was assessed in the tumor tissue in vitro by GLP-1R autoradiography. MAIN OUTCOME MEASURE: The detection rate of insulinomas was measured. RESULTS: In all six cases, the GLP-1R scans successfully detected the insulinomas identified using conventional methods in four cases. By using a gamma-probe intraoperatively, GLP-1R detection permitted a successful surgical removal of the tumors in all patients, diagnosed histopathologically as five pancreatic and one extrapancreatic insulinomas. In vitro GLP-1R autoradiography showed a high density of GLP-1R in all tested insulinomas. CONCLUSION: In vivo GLP-1R imaging is an innovative, noninvasive diagnostic approach that successfully localizes small insulinomas pre- and intraoperatively and that may in the future affect the strategy of insulinoma localization.


Subject(s)
Insulinoma/diagnostic imaging , Pancreatic Neoplasms/diagnostic imaging , Receptors, Glucagon/analysis , Adult , Aged , Female , Glucagon-Like Peptide-1 Receptor , Humans , Indium Radioisotopes , Isotope Labeling/methods , Male , Middle Aged , Radionuclide Imaging , Sensitivity and Specificity
18.
Amino Acids ; 36(3): 501-9, 2009 Mar.
Article in English | MEDLINE | ID: mdl-18528747

ABSTRACT

To determine whether portal plasma flow (PPF) and net portal appearance of amino acids (AA) could be affected by 2-hydroxy-4-methylthiobutyrate (HMB), six barrows (35-day-old, 8.6+/-1.4 kg), implanted with arterial, portal and mesenteric catheters, were fed a DL-methionine (as the control) or HMB-supplemented diet once hourly and infused intramesenterically with 1% p-amino hippurate. PPF was numerically 9% higher (P=0.09) in HMB-fed pigs than in controls over a 4-6 h period. Compared with controls, pigs fed the HMB diet had increased (P<0.05) net portal balance and/or appearance of leucine, isoleucine, histidine, arginine and alanine, but had decreased (P<0.05) portal appearance of glutamate over a 6-h period. The concentration of acetate in the lumen of the distal small intestine was higher (P=0.01) in HMB-fed pigs than in controls (25.14 vs. 7.64 mmol/kg). mRNA levels for proglucagon and endothelial nitric-oxide synthase (eNOS) in stomach and proximal small intestine, and mRNA levels for GLP-2 receptor (GLP-2R) in stomach were higher (P<0.05) in HMB-fed pigs compared with those in controls. Collectively, HMB supplementation increased concentrations of short-chain fatty acids in intestinal lumen, expression of proglucagon, GLP-2R, and eNOS genes, and net portal absorption of AA. These novel findings from the study with pigs may also have important implications for intestinal nutrition and health in humans.


Subject(s)
Amino Acids/blood , Diet , Methionine/analogs & derivatives , Portal System/drug effects , Amino Acids/metabolism , Animals , Fatty Acids/blood , Fatty Acids/metabolism , Glucagon-Like Peptide-2 Receptor , Intestinal Mucosa/metabolism , Intestines/blood supply , Methionine/administration & dosage , Nitric Oxide Synthase Type III/analysis , Portal System/metabolism , Proglucagon/analysis , RNA, Messenger/analysis , Receptors, Glucagon/analysis , Regional Blood Flow/drug effects , Swine
20.
Biopolymers ; 90(3): 287-96, 2008.
Article in English | MEDLINE | ID: mdl-18260137

ABSTRACT

Glucagon is a 29-amino acid polypeptide hormone secreted by pancreatic A cells. Together with insulin, it is an important regulator of glucose metabolism. Type 2 diabetes is characterized by reduced insulin secretion from pancreatic B cells and increased glucose output by the liver which has been attributed to abnormally elevated levels of glucagon. The glucagon receptor (GR) is a member of family B G protein-coupled receptors, ligands for which are peptides composed of 30-40 amino acids. The impetus for studying how glucagon interacts with its membrane receptor is to gain insight into the mechanism of glucagon action in normal physiology as well as in diabetes mellitus. The principal approach toward this goal is to design and synthesize antagonists of glucagon that will bind with high affinity to the GR but will not activate it. Site-directed mutagenesis of the GR has provided some insight into the interactions between glucagon and GR. The rational design of potent antagonists has been hampered by the lack of structural information on receptor-bound glucagon. To obtain adequate amounts of receptor protein for structural studies, a tetracycline-inducible HEK293S GnT1(-) cell line that stably expresses human GR at high-levels was developed. The recombinant receptor protein was characterized, solubilized, and isolated by one-step affinity chromatography. This report describes a feasible approach for the preparation of human GR and other family B GPCRs in the quantities required for structural studies.


Subject(s)
Glucagon/antagonists & inhibitors , Receptors, Glucagon/metabolism , Tetracycline/pharmacology , Adenylyl Cyclases/metabolism , Amino Acid Sequence , Antibodies, Monoclonal/metabolism , Butyrates/pharmacology , Cell Line/drug effects , Cell Membrane/metabolism , Chromatography, Affinity , Enzyme Activation/drug effects , Feasibility Studies , Gene Expression Regulation , Glucagon/chemistry , Glycosylation , Green Fluorescent Proteins/metabolism , Humans , Inhibitory Concentration 50 , Kidney/cytology , Ligands , Models, Chemical , Molecular Sequence Data , Receptors, Glucagon/analysis , Receptors, Glucagon/chemistry , Receptors, Glucagon/genetics , Receptors, Glucagon/isolation & purification , Recombinant Proteins/chemistry , Recombinant Proteins/isolation & purification , Recombinant Proteins/metabolism , Solubility
SELECTION OF CITATIONS
SEARCH DETAIL
...